Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
March 14, 2005
- Interstitial Pneumonia Due to Arava Evaluated: Safety Inf. No. 201
March 14, 2005
- DIAGNOSTIC NEWS IN BRIEF
March 14, 2005
- PMDA Suspends Receipt of Applications for Clinical Trial Consultation
March 14, 2005
- TOPICS 2 articrels
March 14, 2005
- 3-Year Plan on Clinical Trials Enters Last Year
March 14, 2005
- BULLETIN
March 14, 2005
- SJP SEMINAR
March 14, 2005
- REGULATORY NEWS IN BRIEF
March 14, 2005
- NEW PRODUCTS
March 14, 2005
- 3M Pharm, Takeda to Collaborate on Treatment for HPV Infection
March 14, 2005
- Takeda Obtains Candesartan Add. Indication for Heart Failure
March 14, 2005
- DIA Workshop on Clinical Trials Discusses AE Reporting
March 14, 2005
- Execommunications to Acquire Kobashou's Subsidiary Kics
March 14, 2005
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 14, 2005
- Nippon Shinyaku Forecasts 2.1% Growth in Sales for FY2004
March 14, 2005
- PRESS SEMINAR
March 14, 2005
- Mochida's R&D to Focus on Lifestyle Diseases, Chronic Pain
March 14, 2005
- OTC NEWS IN BRIEF
March 14, 2005
- VIWES & OPINIONS
March 14, 2005
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…